Enteris BioPharma to Exhibit at CPhI North America 2022

Rhea-AI Summary

Enteris BioPharma, a subsidiary of SWK Holdings (Nasdaq: SWKH), will exhibit at CPhI North America 2022 from May 17-19 in Philadelphia. The company aims to showcase its innovative drug delivery technologies, including Peptelligence® and ProPerma®, which facilitate the oral delivery of challenging compounds. Enteris also provides comprehensive contract manufacturing services, enhancing its position in the pharmaceutical sector. CEO Rajiv Khosla emphasized the importance of this event for exploring partnerships in drug development and manufacturing.

Positive

• Participation in CPhI North America 2022 enhances visibility in the pharmaceutical industry.
• Showcasing proprietary technologies Peptelligence® and ProPerma® could lead to new business opportunities.
• Enteris BioPharma provides integrated CDMO services, appealing to pharmaceutical companies.

Negative

• None.

BOONTON, N.J., May 4, 2022 /PRNewswire/ -- Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation (Nasdaq: SWKH), announced today that the company will participate in and exhibit at CPhI North America 2022 being held May 17-19, 2022 in Philadelphia (Booth 1708).

During the conference, members of the Enteris management team will host meetings with pharmaceutical executives focused on Peptelligence^® and ProPerma^® the company's novel formulation technologies that enable oral delivery of BCS class III and IV compounds including peptides, peptidomimetics, small molecules, as well as its CMO business segment, which provides custom solutions for the manufacturing of solid oral doses for challenging compounds, including peptides and highly potent small-molecule compounds. Enteris now provides drug product manufacturing in the branded and generic markets, including the manufacture, testing, and release of Phase 1 to Phase 3 clinical trial materials (CTM), and commercial production at a 32,000-square-foot facility that includes 6,000 square feet of cleanroom space with approximately 2,500 square feet dedicated to the containment and processing of high potency active pharmaceutical ingredients (HPAPI).

Rajiv Khosla, Ph.D., Chief Executive Officer of Enteris, stated, "We greatly look forward to participating in CPhI North America 2022 and the opportunity it affords us to showcase our suite of drug delivery technologies as well as manufacturing services to pharmaceutical and biotechnology companies. Whether a company is seeking to outsource the manufacture of solid oral doses for difficult compounds, including HPAPI, or transition their injectable peptide or small molecule drug to oral delivery, Enteris has the expertise and capabilities to capitalize on a variety of partnering opportunities, and it is our intent to maximize this potential to the fullest."

Details are as follows:

Event:	CPhI North America 2022
Date:	May 17-19, 2022
Location:	Pennsylvania Convention Center, Philadelphia, PA
Booth Number:	1708
Website:	https://www.cphi.com/northamerica/en/home.html

About Enteris BioPharma
Enteris BioPharma, Inc. is a wholly-owned subsidiary of SWK Holdings Corporation (Nasdaq: SWKH) offering total integrated contract development and manufacturing (CDMO) services including innovative formulation solutions utilizing its proprietary drug delivery technologies, Peptelligence^® and ProPerma®. The technologies have been the subject of numerous feasibility studies and active development programs, several of which are in clinical development. Additionally, Enteris BioPharma is advancing an innovative internal product pipeline of drug products that address significant unmet clinical needs for which there is no satisfactory treatment option. For more information on Enteris BioPharma and its proprietary oral drug delivery technologies, please visit http://www.EnterisBioPharma.com.

View original content:https://www.prnewswire.com/news-releases/enteris-biopharma-to-exhibit-at-cphi-north-america-2022-301539490.html

SOURCE Enteris BioPharma, Inc.

FAQ

What is the purpose of Enteris BioPharma's participation in CPhI North America 2022?

Enteris BioPharma aims to showcase its drug delivery technologies and contract manufacturing services to attract partnerships.

When is CPhI North America 2022 taking place?

CPhI North America 2022 is scheduled for May 17-19, 2022.

Where is CPhI North America 2022 held?

The event will take place at the Pennsylvania Convention Center in Philadelphia.

What technologies will Enteris BioPharma showcase at CPhI North America 2022?

Enteris will showcase its Peptelligence® and ProPerma® technologies for oral drug delivery.

What services does Enteris BioPharma offer to pharmaceutical companies?

Enteris BioPharma provides contract development and manufacturing services, including the manufacture of solid oral doses.